## Answer
(model generated chain of thought explanation)

Given the patient's history, presentation, and biopsy results, we can deduce the following:

1. **Patient's History**: The patient has a significant smoking history (30-pack-year), which is a major risk factor for lung cancer.
2. **Initial Findings**: A solitary 5-mm solid nodule in the upper lobe of the right lung on follow-up CT, with an increase in size to 2 cm and ipsilateral mediastinal lymph node involvement.
3. **Biopsy Results**: Small, dark blue tumor cells with hyperchromatic nuclei and scarce cytoplasm, which are characteristic of adenocarcinoma, a common type of non-small cell lung cancer (NSCLC).
4. **MRI and Scintigraphy Findings**: No evidence of other metastases.

Considering these findings, the most appropriate next step in management would be to confirm the diagnosis and assess for potential treatment options.

## Step 1: Confirm the Diagnosis
The biopsy results are consistent with adenocarcinoma, which is a common type of lung cancer. Therefore, we need to confirm this diagnosis through further evaluation.

## Step 2: Assess Treatment Options
Given the patient's age (48 years) and smoking history, it is essential to consider treatment options that are effective for early-stage NSCLC.

- **A. Wedge Resection**: This surgical procedure involves removing a wedge of lung tissue from one side of the lobe containing the nodule. While it can be an option for some patients, it may not be sufficient for adenocarcinoma.
- **B. Cisplatin-etoposide Therapy and Radiotherapy**: This combination chemotherapy regimen is often used for non-small cell lung cancer, including adenocarcinoma. However, the patient's age and lack of evidence of metastases make this option less suitable at this stage.
- **C. Right Lobectomy**: This surgical procedure involves removing the entire right lobe of the lung. Given the patient's age and the fact that the nodule is located in the upper lobe, lobectomy may be a reasonable option to consider.
- **D. Gefitinib Therapy**: This targeted therapy is specifically designed for patients with specific genetic mutations (e.g., EGFR mutation). While it can be effective for certain types of lung cancer, it is not typically considered as an initial treatment option for adenocarcinoma.

